复方芪术汤联合替比夫定对HBeAg阳性慢性乙型肝炎患者HBeAg血清学转换作用的临床研究
发布时间：2018-08-25 14:14
【摘要】：目的：复方芪术汤联合替比夫定治疗e抗原(Hepatitis B e antigen, HBeAg)阳性慢性乙型肝炎(chronic hepatitis B, CHB)患者,评价其对HBeAg阳性慢性乙型肝炎患者HBeAg血清学转换作用。方法：纳入104例HBeAg阳性CHB初治患者,随机分为实验组和对照组,均接受替比夫定600mg/日为基础治疗,实验组加用中药复方芪术汤,疗程1年,分析比较0、4、12、24及52周时HBeAg、HBV DNA.肝肾功能及细胞免疫变化情况。结果：①12、24、52周时,实验组HBeAg血清学转换率分别为8.33%、33.33%、43.75%；对照组分别为3.57%、12.5%、32.14%,实验组HBeAg血清学转换率均高于对照组,但差别无统计学意义。②疗程结束时,实验组CD4+T和CD8+T细胞水平较对照组升高(P0.05)；实验组与对照组HBV DNA转阴率分别为68.75%和64.29%；丙氨酸氨基转移酶(alanine transaminase,ALT)复常率分别为77.08%和75%(P0.05),差别无统计学意义；③实验组患者疗程结束后CD4+T及CD8+T细胞计数分别为750(685.50,953)和527(474,651.50),较开始治疗前升高(P0.05),对照组CD4+T及CD8+T细胞分别为628.50(557.50,712)和467.50(421,537),在治疗前后无明显变化(P0.05)。结论：复方芪术汤联合替比夫定治疗可能通过提高细胞免疫功能增加HBeAg阳性慢性乙型肝炎患者HBeAg血清学转换率。
[Abstract]:Objective: to evaluate the effect of compound Qizhutang combined with tibivudine on HBeAg serological conversion in patients with HBeAg positive chronic hepatitis B (chronic hepatitis B, CHB). Methods: 104 patients with HBeAg positive CHB were randomly divided into two groups: the experimental group and the control group. All patients received tibivudine 600mg/ day as the basic treatment. The experimental group was treated with traditional Chinese medicine compound Qizu decoction. The course of treatment was 1 year. The HBeAg,HBV DNA. was analyzed and compared at 24 and 52 weeks after treatment. Changes of liver and kidney function and cellular immunity. Results the serological conversion rate of HBeAg in the experimental group was 8.33 and 33.33 respectively at the 52nd week of the control group, and that in the control group was 3.57 and 12.55.The serological conversion rate of HBeAg in the experimental group was higher than that in the control group, but there was no significant difference at the end of the course of treatment. The levels of CD4 T and CD8 T cells in the experimental group were higher than those in the control group (P0.05), the negative rates of HBV DNA in the experimental group and the control group were 68.75% and 64.29 respectively, and the relapse rates of alanine aminotransferase (alanine transaminase,ALT) were 77.08% and 75% (P0.05), respectively. 3After the course of treatment, the counts of CD4 T and CD8 T cells were 750 (685.50953) and 527 (474651.50), respectively, which were higher than those before treatment (P0.05). The CD4 T and CD8 T cells in the control group were 628.50 (557.50712) and 467.50 (421537), respectively. There was no significant change before and after treatment (P0.05). Conclusion: compound Qizhutang combined with tibivudine may increase the HBeAg serological conversion rate in patients with HBeAg positive chronic hepatitis B by improving the cellular immune function.
【学位授予单位】：复旦大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R512.62
本文编号：2203121
[Abstract]:Objective: to evaluate the effect of compound Qizhutang combined with tibivudine on HBeAg serological conversion in patients with HBeAg positive chronic hepatitis B (chronic hepatitis B, CHB). Methods: 104 patients with HBeAg positive CHB were randomly divided into two groups: the experimental group and the control group. All patients received tibivudine 600mg/ day as the basic treatment. The experimental group was treated with traditional Chinese medicine compound Qizu decoction. The course of treatment was 1 year. The HBeAg,HBV DNA. was analyzed and compared at 24 and 52 weeks after treatment. Changes of liver and kidney function and cellular immunity. Results the serological conversion rate of HBeAg in the experimental group was 8.33 and 33.33 respectively at the 52nd week of the control group, and that in the control group was 3.57 and 12.55.The serological conversion rate of HBeAg in the experimental group was higher than that in the control group, but there was no significant difference at the end of the course of treatment. The levels of CD4 T and CD8 T cells in the experimental group were higher than those in the control group (P0.05), the negative rates of HBV DNA in the experimental group and the control group were 68.75% and 64.29 respectively, and the relapse rates of alanine aminotransferase (alanine transaminase,ALT) were 77.08% and 75% (P0.05), respectively. 3After the course of treatment, the counts of CD4 T and CD8 T cells were 750 (685.50953) and 527 (474651.50), respectively, which were higher than those before treatment (P0.05). The CD4 T and CD8 T cells in the control group were 628.50 (557.50712) and 467.50 (421537), respectively. There was no significant change before and after treatment (P0.05). Conclusion: compound Qizhutang combined with tibivudine may increase the HBeAg serological conversion rate in patients with HBeAg positive chronic hepatitis B by improving the cellular immune function.
【学位授予单位】：复旦大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R512.62
【参考文献】
相关期刊论文 前3条
1 周利;中药合甘利欣治疗慢性乙型病毒性肝炎90例[J];广西中医药;2003年03期
2 沈文梅,王成彬,汪德清,田亚平,颜光涛,郝秀华;黄芪总黄酮对失血性休克再灌注肝损伤的防护作用[J];中国药理学通报;1997年06期
3 梁月兰;黄春新;;治疗慢性乙肝新药——素比伏(替比夫定片)[J];中南药学;2007年03期
，本文编号：2203121
本文链接：https://www.wllwen.com/yixuelunwen/chuanranbingxuelunwen/2203121.html
最近更新
教材专著
